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Summary The outlook for patients with colorectal liver metastases is poor. Microspheres have been com-
bined with cytotoxics and administered via the hepatic artery in an attempt to improve tumour drug exposure
within the liver. However, it has been suggested that arteriovenous connections might occur in association with
intrahepatic tumours causing loss of regional advantage, and that the administration of microspheres further
exacerbates arteriovenous shunting. In seven patients with colorectal liver metastases, base-line shunting was
measured using a tracer quantity of radio-labelled albumin microspheres. The shunted fraction of a 'thera-
peutic quantity' of microspheres was subsequently measured in the same group of patients using albumin
microspheres carrying a different radio-label. Base-line shunt for 0.5 x 106 microspheres was found to be
2.2 ± 1.8% (mean ±s.d.); the percentage shunt of a therapeutic quantity (40-80 x 106) of microspheres was
3.0±0.8%. We conclude that arteriovenous shunting in patients with colorectal liver metastases is minimal,
and is not significantly increased by the administration of therapeutic quantity of microspheres during regional
chemotherapy.
Conventional treatment of colorectal liver metastases has
yielded disappointing results, and attention has turned to
hepatic arterial chemotherapy. The potential advantages of
regional therapy over systemic drug administration are that
high drug levels can be achieved in the tumour-bearing organ
and that systemic drug concentrations fall when the drug is
retained within the organ, thereby minimising toxicity.
Particle-bound regional chemotherapy has been used in an
attempt to improve drug uptake by the target organ. There
are two mechanisms of value. Firstly, cytotoxic drugs have
been co-administered with biodegradable microspheres which
temporarily slow hepatic arterial blood-flow in the tumour-
bearing liver and increase uptake of drug by the cells (Dakhil
et al., 1982; Thom et al., 1989). Secondly, anti-cancer agents,
including Adriamycin, mitomycin C, 5 fluorouracil, cis-platin
and cytocidal radio-nuclides have been loaded into particles
which act as controlled release vehicles in the target tissue
(McArdle et al., 1988; Fujimoto et al., 1985; Okamoto et al.,
1986; Herba et al., 1988).
If, however, arteriovenous shunting were associated with
liver metastases (Zeissman et al., 1983), a proportion of
arterially administered drug would bypass vascular beds in
the tumour-bearing liver and be carried to the lungs. The
effect would be to reduce tumour drug exposure, increase
systemic side-effects and in the case of some particle-bound
cytotoxics, increase pulmonary toxicity.
With both approaches for enhancing regional therapy,
relatively large numbers of particles may be required, either
because of the relatively low drug pay-loads associated with
some cytotoxic-loaded microspheres, or in order to optimise
the arrest of arterial blood-flow. Unfortunately, there have
been reports that very high levels of shunting occur when
large numbers of microspheres are injected into the hepatic
artery (Starkhammar et al., 1987).
The aim of this study is to establish the level of base-line
shunting and the effect of a therapeutic quantity of micro-
spheres on shunting.
Patients and methods
Microsphere preparation
It was necessary to design a radio-pharmaceutical specifically
for this study. The requirements were for sterile radio-active
microspheres (diameter 20-401tm) which were bio-compati-
ble, could be imaged by gamma camera, made in batches
containing between 40 and 80 x 106 particles, and from
which the activity would not leach.
"3'I-labelled albumin microspheres were made in the fol-
lowing way. Under sterile conditions, 4.5 mg of '3'I-human
serum albumin (Medgenix, Brussels) supplied at a concentra-
tion of 20 mg ml-' was mixed with a solution of 380 mg cold
human serum albumin (Sigma Chemicals) dissolved in 800 jil
water containing 2 mg sodium dodecylsulphate. This con-
situted the disperse phase of a water in oil emulsion which
was prepared with a Silverson mixer. The droplets were
stablised by the addition of 240ItI 15% glutaraldehyde solu-
tion and the resulting microspheres separated and made
ready for in vivo use as described elsewhere (Willmott et al.,
1985). For each batch of particles, the 50% weight average
fell within the range of 25-40ytm.
The radiopharmaceutical was stable in air. In phosphate
buffered saline, more than 99.7% of activity remained
particle-bound after 2 months. The preparation was also
remarkably stable in plasma. To check the stability of the
radiolabelled particles in plasma, 2 mg of microspheres were
incubated in 0.5 ml of serum at 37C and after 10 days,
particles were separated from supernatant and radioactivity
in both measured. The amount of 1311 released was expressed
as a percentage of total activity. Between 92 and 96% of the
original activity remained microsphere-bound after 10 days
(median of 95%, n = 6).
A further in vitro experiment was performed to measure
the sensitivity of albumin microspheres to protease digestion.
Microspheres were incubated in a 0.4% trypsin solution at
37°C and degradation and solubilisation of particles record-
ed. The break-down pattern of microspheres by protease had
a lag-phase which preceded swelling of the particles and was
followed by degradation which was complete after 4 h (Will-
mott et al., 1989).
Patients
Seven patients with advanced colorectal liver metastases and
indwelling hepatic artery perfusion catheters were included in
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the study. Informed consent was obtained. The extent of
disease was assessed by tin colloid scan (less than 25% of
liver mass in one; between 25 and 50% in four; greater than
50% in two). Each patient underwent two studies:
(a) An assessment of base-line arteriovenous shunting to
lung for tracer quantities of microspheres;
(b) Measurement of the shunted fraction of a therapeutic
quantity of microspheres.
The base-line shunt measurement was performed by inject-
ing approximately half a million freshly prepared technetium
labelled albumin microspheres (particle diameter 20-40gs,
Sorin Biomedica) via an hepatic artery catheter using a glass
syringe. The activity of this tracer dose of particles was
approximately 80 MBq. The liver and lungs were imaged by
placing the patient supine under the gamma camera (IGE
400A Tomographic gamma camera with low energy, parallel
hole general purpose collimator).
For the assessment of shunting of a 'therapeutic quantity'
of albumin microspheres, 131I albumin microspheres were
used. All patients were commenced on potassium iodate 2
days prior to administration of microspheres in order to
prevent uptake of released radioactive "31I by the thyroid
gland. This was continued for 14 days after microsphere
administration.
The patient was positioned supine on the couch of the
gamma camera (IGE 400A Tomographic gamma camera
with high energy, parallel hole collimator was used). For
each study, 200 mg of freshly prepared '311-Albumin micro-
spheres (containing between 40 and 80 x 106 particles and
between 2.7 and 8.7 MBq of activity) were drawn into a glass
syringe, infused as a bolus into the hepatic artery catheter
and the syringe flushed with 10 ml of saline to maximise
delivery.
Anterior and posterior images of both lungs and liver were
acquired immediately following injection of microspheres.
Scans were acquired for 5 min or 500,000 counts, and stored
on a dedicated computer in a 128 x 128 format (MAPS 2000,
Link Analytical Ltd).
For each study, regions of interest were drawn on the
images of the lung-fields from both the anterior and posterior
views (excluding the cardiac region). A background region
was drawn just outside the patient image, adjacent to the left
lung. The geometric mean of the net anterior and posterior
count rates was then found. Regions of interest were also
drawn around the liver on both anterior and posterior views
and the geometric mean of the net count rate found. The
arteriovenous shunt percentage was calculated using the fol-
lowing formula:
Lung count rate x 100 %
Liver + Lung count rate
Results
The results are summarised in Table I. The median percent
shunt was 1.3% at base-line. The median shunt after the
therapeutic bolus of microspheres was 2.8%. The difference
was not significant in relation to the errors of measurement.
Discussion
High levels of base-line shunting (up to 26%) have been
reported in patients with metastatic liver disease, and much
higher levels have been reported when large numbers of
biodegradable microspheres are co-administered with chemo-
therapy (Starkhammar et al., 1987; Ensminger et al., 1985).
The radioactive particles used to measure arteriovenous
shunting in these studies were macro-aggregates of albumin,
surface-labelled with technetium. Potential errors with this
Table I Relative lung uptake in seven patients with advanced liver
metastases
Patient Base-line shunt (%) % oftherapeutic dose shunted
5 x JO microspheres 4-8 x 107 microspheres
1 1.2 2.4
2 6.0 3.8
3 1.4 3.6
4 1.3 2.6
5 1.1 2.8
6 3.1 4.1
7 1.2 1.8
radio-pharmaceutical include leaching of activity, the wide
range of particle size (especially the diameter of the smallest
particles), and the affinity of albumin aggregates for adminis-
tration equipment (Palmer, 1985). Indeed we have previously
shown that base-line shunting is minimal when these sources
of error are accounted for (Goldberg et al., 1987).
In the present study, in an attempt to circumvent these
problems, we have used commercially available surface radio-
labelled albumin microspheres with careful attention to
preparation and handling, and the use of glass syringes to
reduce the amount of free pertechnetate. Consequently, we
have found values of base-line arterio-venous shunting to be
consistently low, with only an exceptional value as high as
6% and five of seven values less than 1.5% (Table I). to
assess the likelihood that free pertechnetate was the cause of
the 6% result, a background area over the sternum was
defined which would be expected to contain a contribution
from blood-pool activity not trapped within the lung.
Repeating the shunt calculation with this background gave a
lung shunt percentage of 3.2%.
Little is known about the effect on shunting of the hepatic
arterial injection of large numbers of particles, but it is
important to exclude the potential loss of regional selectivity
during hepatic arterial therapy. This would not only have a
bearing on tumour exposure to the drug, but also increase
pulmonary or systemic toxicity, depending on the cytotoxic
formulation.
In this study, shunting was assessed during administration
of a large quantity ofparticles which would be comparable in
number to that used in a therapeutic setting. The number
used had been found to be near the limit of tolerance in pilot
studies for co-administration chemotherapy and biodegrad-
able microspheres (Goldberg et al., 1988). The use of com-
mercially available surface-labelled albumin microspheres was
not feasible when measuring the shunt associated with large
numbers of microspheres because of the number of aliquots
of microspheres required for the injectate, and their poor
stability in air. Our customised '311-labelled albumin micro-
spheres proved to be a superior radio-pharmaceutical because
of the covalent binding of the isotope throughout the particle
matrix, resulting in minimal leaching of free radio-activity
into the circulation.
In this study, we have confirmed that low levels of shun-
ting occur in patients with colorectal liver metastases and the
level of shunting is not significantly increased when large
numbers of microspheres are administered via the hepatic
artery. Arteriovenous shunting is therefore unlikely to inc-
rease the morbidity associated with particle-based therapy for
patients in colorectal liver metastases.
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